Feingold Jay
Known title: Chief Medical OfficerCIK: 0001885838
Associated companies
Transaction History
| PYXS | ▲ Buy | Grant | 209,803 | $0 | 3/24/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 53,931 | $0 | 1/3/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 115,931 | $0 | 4/14/2022 | View on chart |
| PYXS | ▲ Buy | Grant | 306,930 | $0 | 3/31/2022 | View on chart |
| PYXS | ▲ Buy | Grant | 43,750 | $0 | 10/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops
Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops. Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.